LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Ionis Pharmaceuticals to present at upcoming investor conferences

March 28, 2023 | Last Trade: US$42.62 0.13 -0.30

CARLSBAD, Calif., March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences:

  • Guggenheim Virtual Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023
  • 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023

A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. The replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page